Fig. 7From: Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traitsThe schematic diagram of the molecular mechanisms by which melatonin synergizes vemurafenib in melanoma treatment. The symbol (⊦) indicates negative regulation. The arrow (→) indicates direct or indirect positive regulationBack to article page